Prospecto:information for the patient
Ebymect 5mg/850mg film-coated tablets
Ebymect 5mg/1.000mg film-coated tablets
dapagliflozina/hidrocloruro de metformina
Read this prospectus carefully before starting to takethismedicine, because it contains important information for you.
Ebymect contains two active ingredients called dapagliflozina and metformina. Both belong to a group of medications known as “oral antidiabetics”. These are medications taken orally for diabetes.
Ebymect is used for a type of diabetes called “type 2 diabetes” in adult patients (18 years of age or older). If you have type 2 diabetes, your pancreas does not produce enough insulin or your body is unable to use the insulin it produces properly. This leads to high levels of sugar (glucose) in your blood.
For treating type 2 diabetes:
It is essential that you continue following the dietary and exercise recommendations provided by your doctor, pharmacist, or nurse.
Do not take Ebymect:
Do not take this medication if any of the above situations apply.
Warnings and precautions
Risk of lactic acidosis
Ebymect may cause a very rare but serious side effect, called lactic acidosis, especially if your kidneys do not function properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting or alcohol consumption, dehydration (see more information below), liver problems, and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart disease).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking Ebymect for a short period of time if you have a condition that may be associated with dehydration(significant loss of body fluids), such as intense vomiting, diarrhea, fever, exposure to heat, or if you drink less liquid than normal. Consult your doctor for further instructions.
Stop taking Ebymect and contact a doctor or the nearest hospital immediately if you experience any of the symptoms that produce lactic acidosis,as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and should be treated in a hospital.
Consult your doctor, pharmacist, or nurse before starting to take Ebymect, and during treatment:
If any of the above situations apply to you (or you are unsure), speak with your doctor, pharmacist, or nurse before taking this medication.
Consult your doctor immediately if you experience a combination of symptoms such as pain, tenderness, redness, or inflammation of the genitals or the area between the genitals and the anus, with fever or general discomfort. These symptoms may be a sign of a rare but serious, potentially life-threatening infection called fasciitis necrosante del perineo or gangrene of Fournier, which destroys tissue under the skin. Gangrene of Fournier should be treated immediately.
Surgery
If you need to undergo major surgery, stop taking Ebymect while the procedure is being performed and for a period of time afterwards. Your doctor will decide when to interrupt treatment with Ebymect and when to restart it.
Kidney function
Your kidneys should be checked before starting to take Ebymect. During treatment withthis medication, your doctor will check your kidney function once a year or more frequently if you are an older person and/or if your kidney function is worsening.
Care of the feet
It is essential to regularly check your feet and follow any other foot care advice provided by your healthcare professional.
Blood glucose in urine
Due to howthis medicationworks, your urine will test positive for glucose while you aretaking this medication.
Older age(≥65years or more)
If you are an older person, there may be a higher risk of your kidneys functioning poorly and being treated with other medications (see also “Kidney function” above and “Taking Ebymect with other medications” below).
Children and adolescents
This medicationis not recommended for children or adolescents under 18years of age, as it has not been studied in these patients.
Other medications and Ebymect
If you need to be administered an injection of a contrast medium containing iodine, for example, in the context of a radiograph or examination, stop taking Ebymect before the injection or at the time of the injection. Your doctor will decide when to interrupt treatment with Ebymect and when to restart it.
Inform your doctor if you are taking, have taken recently, or may need to take any other medication. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Ebymect. It is especially important to mention the following:
Taking Ebymect with alcohol
Avoid excessive alcohol consumption while taking Ebymect, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before taking this medication. You should stop taking this medication if you become pregnant, as it is not recommended for use during the second and third trimesters of pregnancy (the last six months). Consult your doctor about the best way to control blood glucose levels during pregnancy.
Consult your doctor if you want to breastfeed or are breastfeeding before taking this medication. Do not usethis medicationwhile breastfeeding. Metformin passes into breast milk in small amounts. It is unknown whether dapagliflozina passes into breast milk.
Driving and using machines
This medication has no or insignificant effect on your ability to drive or use machines. Taking it with other medications that lower blood sugar levels, such as insulin or a “sulfonilurea” type medication, may cause very low blood sugar levels (hypoglycemia), which may cause symptoms such as weakness, dizziness, increased sweating, rapid heart rate, visual disturbances, or difficulty concentrating, which may affect your ability to drive or use machines. Do not drive or use tools or machines if you start to feel these symptoms.
Ebymect contains sodium
This medication contains less than 1mmol of sodium (23mg) per dose, which is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor.This medication.In case of doubt, consult your doctor or pharmacist again.
How much to take
How to take this medication
Your doctor may prescribe you this medicationalong with another medication(s)to reduce the amount of sugar in your blood. These may be oral medications or administered by injection, such as insulin or a GLP‑1 receptor agonist. Remember to take these other medication(s) following your doctor's instructions. This will help you achieve the best results for your health.
Diet and exercise
To control your diabetes, you must continue with the diet and exercise, even when taking this medication. Therefore, it is essential that you continue following the dietary and exercise recommendations from your doctor, pharmacist, or nurse. In particular, if you are following a weight control diet for diabetics, continue with it while takingthis medication.
If you take more Ebymect than you should
If you take more tablets of Ebymect than you should, you may experience lactic acidosis. Symptoms of lactic acidosis include having many nausea or vomiting, stomach pain, muscle cramps, intense fatigue, or difficulty breathing. If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. Stop taking this medication immediately and contact a doctor or the nearest hospital right away (see section2). Bring the medication packaging with you.
If you forgot to take Ebymect
If you forgot a dose, take it as soon as you remember. If you do not remember until it is time for the next dose, skip the missed dose and follow your regular schedule. Do not take a double dose ofthis medicationto compensate for the missed doses.
If you interrupt treatment with Ebymect
Do not stop takingthis medicationwithout consulting your doctor first. Your blood sugar levels may increase without this medication.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Ebymect and consult a doctor immediately if you notice any of these severe or potentially severe side effects:
Ebymect can cause a very rare but serious side effect called lactic acidosis (see section 2 “Warnings and precautions”), If this happens to you,you must stop taking Ebymect and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
Contact a doctor or the nearest hospital immediately if you experience any of the following side effects:
These are the signs of diabetic ketoacidosis (see also section 2 “Warnings and precautions”):
This can occur despite normal blood glucose levels. Your doctor must decide whether to temporarily or permanently interrupt your treatment with Ebymect.
Stop taking Ebymect and consult a doctor as soon as possible if you notice any of the following severe or potentially severe side effects:
These are the signs of a severe urinary tract infection:
Although it is rare, if you observe blood in your urine, report it to your doctor immediately.
Contact a doctor as soon as possible if you experience any of the following side effects:
The signs of low blood sugar are:
Your doctor will explain how to treat low blood sugar and what to do if you experience any of the above symptoms. If you have symptoms of low blood sugar, take glucose tablets, a sweet snack, or drink a fruit juice. Measure your blood sugar level, if possible, and rest.
Other side effects include:
Very common
Common
Rare(may affect up to 1 in 100 people)
Very rare
Reporting of side effects
If you experience any type of side effect, consulta doctor,pharmacistor nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theAppendix Vnational notification system included in the
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack or container after EXP/CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications you no longer need. In this way, you will help protect the environment.
Composition of Ebymect
Each film-coated tablet (tablet) of Ebymect 5 mg/850 mg contains dapagliflozina propanodiol monohydrate equivalent to 5 mg of dapagliflozina and 850 mg of hydrochloride of metformin.
Each film-coated tablet (tablet) of Ebymect 5 mg/1,000 mg contains dapagliflozina propanodiol monohydrate equivalent to 5 mg of dapagliflozina and 1,000 mg of hydrochloride of metformin.
Appearance of the product and contents of the package
Ebymect 5 mg/850 mg film-coated tablets and Ebymect 5 mg/1,000 mg film-coated tablets are available in PVC/PCTFE/Alu blisters. The package sizes are 14, 28, 56, and 196 (2 x 98) film-coated tablets in calendar-blistered packs of 14 film-coated tablets, 60 film-coated tablets in non-precortated blisters of 10 film-coated tablets, and 60 x 1 film-coated tablets in pre-cortated single-dose blisters.
Only some package sizes may be marketed in your country.
Marketing authorization holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden
Responsible for manufacturing
AstraZeneca AB
Gärtunavägen
SE-152 57 Södertälje
Sweden
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660550 |
Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11 | Ceská republika AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 111 |
Danmark AstraZeneca A/S Tlf.: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 |
Deutschland AstraZeneca GmbH Tel: +49 40 809034100 | Nederland AstraZeneca BV Tel: +31 85 808 9900 |
Eesti AstraZeneca Tel: +372 6549 600 | Norge AstraZeneca AS Tlf: +47 21 00 64 00 |
Ελλ?δα AstraZeneca A.E. Τηλ: +30 2 106871500 | Österreich AstraZeneca Österreich GmbH Tel: +43 1 711 3100 |
España Esteve Pharmaceuticals, S.A. Tel: +34 93 446 60 00 Laboratorio Tau, S. A. Tel: +34 91 301 91 00 | Polska AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00 |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal BIAL-Portela & Cª., S.A. Tel.: +351 22 986 61 00 |
Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 000 | România AstraZeneca Pharma SRL Tel: +40 21 317 60 41 |
Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100 | Slovenija AstraZeneca UK Limited Tel: +386 1 5135 600 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika AstraZeneca AB, o.z. Tel: +421 2 5737 7777 |
Italia AstraZeneca S.p.A. Tel: +39 02 0704500 | Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 |
Κ?προς Αλ?κτωρ Φαρ µ ακευτικ? Λτδ Τηλ : +3 57 22490305 | Sverige AstraZeneca AB Tel: +46 8 553 26 000 |
Latvija SIA AstraZeneca Latvija Tel: +371 67377100 | United Kingdom AstraZeneca UK Ltd Tel: +44 1582 836 836 |
Last updated date of this summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.